[go: up one dir, main page]

WO2021209800A1 - Traitement d'une infection humaine par le coronavirus et le virus de la grippe (h1n1) (grippe porcine.) - Google Patents

Traitement d'une infection humaine par le coronavirus et le virus de la grippe (h1n1) (grippe porcine.) Download PDF

Info

Publication number
WO2021209800A1
WO2021209800A1 PCT/IB2020/055997 IB2020055997W WO2021209800A1 WO 2021209800 A1 WO2021209800 A1 WO 2021209800A1 IB 2020055997 W IB2020055997 W IB 2020055997W WO 2021209800 A1 WO2021209800 A1 WO 2021209800A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
treatment
vitamin
dose
grams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2020/055997
Other languages
English (en)
Inventor
Mohamed Khairy Abd Ellatif ELHAYESH
Mervat Mahmoud Hassan Elsayed Hamam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/IB2020/055997 priority Critical patent/WO2021209800A1/fr
Publication of WO2021209800A1 publication Critical patent/WO2021209800A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof

Definitions

  • Corona virus particularly Corona virus (COVID-19) and Influenza virus (H1N1) are viruses that can cause serious medical conditions, it leads to the death of some infected people, so it was important to find a medicine to treat patients and find a vaccine to protect people from the disease.
  • Vitamin C 2 grams as a single dose Orally
  • (1,5 grams as a single dose by injection) the dose can be repeat if needed .
  • Vitamin C (Ascorbic Acid) destroy and eliminate Corona virus (COVID-19) or Influenza Virus (H1N1) in the human body infected with the virus, without the intervention of the immune system of the human body, in this case Vitamin C is antiviral.
  • Vitamin C Ascorbic Acid
  • determining the appropriate dose of the Medicine where the treatment for any disease depends on (determining the disease - then determine the medicine - then determining the appropriate dose of the medicine - then determining the duration of treatment ), in the case of dose reducer the desired healing is not achieved, for example if the doctor recommends taking an antibiotic, at a dose of 1000 milligrams every 12 hours, it is not right to take the same antibiotic at a dose of 100 milligrams every 24 hours, to achieve the recovery of the disease .
  • the normal dose used to treat certain diseases is (1) gram of Vitamin C, and the big dose required to eliminate the Corona virus ( 2 grams as a single dose orally ), it is the appropriate dose to eliminate the Corona virus ( COVID-19 ) or Influenza virus (H1N1), in the human body infected with the virus.
  • Symptoms of the disease (as mentioned by the World Health Organization), represented in (sore throat - dry cough - loss of sense of smell - headache - high temperature - pain in the body - fever - in a few cases appear diarrhea - in very few cases appear vomiting - increased heart rate after several days of the appearance of symptoms - and there are other symptoms ), there's no nose excretion, the order of the appearance of symptoms may vary from person to person, some symptoms may not appear, their severity varies from person to person, depends on the age of the patient and according to the strength of his immune system. .3 - Treatment (divided into four levels) which are :
  • Vitamin C 2 grams as a single dose orally
  • the dose can be repeat only a second time after 8 hours from taking the first dose, which is ( 1 or 2 grams orally)
  • the benefit of Vitamin C is destroy the virus, best takes with him Lemon Juice , and the patient will notice improvement in less than 6 hours.
  • the disease can be prevent by using Vitamin C at small dose (one dose as 1 gram every 2 days ) and can also use Lemon Juice.
  • Vitamin C one dose as 1 gram every 2 days
  • Lemon Juice Treatment of Influenza virus (H1N1) infection, will review the symptoms of Influenza virus infection then the treatment. .1 - Symptoms of the disease on the infected human:
  • H1N1 Influenza virus
  • Vitamin C 2 grams as a single dose orally
  • 1,5 grams as a single dose by injection the dose can be repeat only a second time after 8 hours from taking the first dose, which is ( 1 or 2 grams orally), and the benefit of the Vitamin C is to eliminate the virus after its destroy and best takes with him Lemon juice, the patient will notice improvement in less than 6 hours.
  • - Vitamin C can be used to treat Influenza (H3N1 - H3N2 - H1N2 ), such as Influenza (H1N1).
  • - Ascorbic Acid ( Vitamin C ) is antiviral, it can destroy some viruses using big dose per one dose ( 2 grams as a single dose orally or 1,5 grams as a single dose by injection ) , the dose can be repeat .
  • a small dose e.g.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le traitement de patients contre le coronavirus (COVID-19) ou le virus de la grippe (H1N1) fait appel à une grosse dose de vitamine C (acide ascorbique) (2 grammes en dose unique par voie orale) ou (1,5 grammes en dose unique par injection), et l'effet de cette grosse dose de vitamine C est d'éliminer et de détruire le virus, sans intervention du système immunitaire du corps humain. Dans ce cas, la vitamine C (acide ascorbique) est antivirale. Le traitement est pris au moment où les symptômes de la maladie commencent à se faire sentir. La dose peut être répétée une fois 8 heures après pour confirmer la destruction du virus. Un médicament antibiotique doit être pris en cas d'apparition de symptômes graves de la maladie et en cas de survenue d'une inflammation microbienne chez le patient.
PCT/IB2020/055997 2020-06-25 2020-06-25 Traitement d'une infection humaine par le coronavirus et le virus de la grippe (h1n1) (grippe porcine.) Ceased WO2021209800A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2020/055997 WO2021209800A1 (fr) 2020-06-25 2020-06-25 Traitement d'une infection humaine par le coronavirus et le virus de la grippe (h1n1) (grippe porcine.)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2020/055997 WO2021209800A1 (fr) 2020-06-25 2020-06-25 Traitement d'une infection humaine par le coronavirus et le virus de la grippe (h1n1) (grippe porcine.)

Publications (1)

Publication Number Publication Date
WO2021209800A1 true WO2021209800A1 (fr) 2021-10-21

Family

ID=71527835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/055997 Ceased WO2021209800A1 (fr) 2020-06-25 2020-06-25 Traitement d'une infection humaine par le coronavirus et le virus de la grippe (h1n1) (grippe porcine.)

Country Status (1)

Country Link
WO (1) WO2021209800A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003052A1 (fr) * 1990-08-23 1992-03-05 Jariwalla Raxit J Procede pour supprimer par l'ascorbate la replication du vih en cas d'infection chronique et aigüe par le vih

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003052A1 (fr) * 1990-08-23 1992-03-05 Jariwalla Raxit J Procede pour supprimer par l'ascorbate la replication du vih en cas d'infection chronique et aigüe par le vih

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANON: "Position Statement Ascorbic Acid: Intravenous high dose in COVID-19", 28 April 2020 (2020-04-28), pages 1 - 2, XP055782392, Retrieved from the Internet <URL:https://www.safetyandquality.gov.au/sites/default/files/2020-05/covid-19_-_position_statement_-_ascorbic_acid_intravenous_high_dose_-_28_april_2020.pdf> [retrieved on 20210305] *
CAI YING ET AL: "A New Mechanism of Vitamin C Effects on A/FM/1/47(H1N1) Virus-Induced Pneumonia in Restraint-Stressed Mice", BIOMED RESEARCH INTERNATIONAL, vol. 2015, 1 January 2015 (2015-01-01), pages 1 - 12, XP055783519, ISSN: 2314-6133, Retrieved from the Internet <URL:http://downloads.hindawi.com/journals/bmri/2015/675149.pdf> DOI: 10.1155/2015/675149 *
CARR ANITRA C.: "A new clinical trial to test high-dose vitamin C in patients with COVID-19", CRITICAL CARE, vol. 24, 7 April 2020 (2020-04-07), pages 133 - 134, XP055782386, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s13054-020-02851-4/fulltext.html> DOI: 10.1186/s13054-020-02851-4 *
DONALDSON VALERIE: "Vitamin C Benefits and COVID-19 (Coronavirus). Case Studies, Reports. Regenerative Medicine Center | Regenerative Medicine Center - Dr. Valerie Donaldson MD Pittsburgh, Pennsylvania PA", 17 June 2020 (2020-06-17), XP055782989, Retrieved from the Internet <URL:https://regenerativemc.com/vitamin-c-and-covid-19/> [retrieved on 20210308] *
LINLING C: "Pharmacologic ascorbate treatment of influenza in vivo", CHIN J TUBERC RESPIR DIS, vol. 37, no. 5, 12 May 2014 (2014-05-12), pages 356 - 359, XP055783524, Retrieved from the Internet <URL:http://rs.yiigle.com/CN112147201405/859920.htm> *
LIU FANG ET AL: "Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial", BMJ OPEN, vol. 10, no. 7, 8 July 2020 (2020-07-08), pages e039519, XP055782918, ISSN: 2044-6055, Retrieved from the Internet <URL:https://bmjopen.bmj.com/content/bmjopen/10/7/e039519.full.pdf> DOI: 10.1136/bmjopen-2020-039519 *
LÓPEZ-ALCALDE JESÚS ET AL: "Effectiveness of vitamin C to treat COVID-19: an overview", 14 April 2020 (2020-04-14), XP055782384, Retrieved from the Internet <URL:http://www.iki.usz.ch/forschung/PublishingImages/Seiten/projekte/Final%20Report%20Vit%20C_Coronavirus_20200414.pdf> [retrieved on 20210305] *
PAWAR ASHISH YASHWANTRAO: "Combating devastating COVID-19 by drug repurposing", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, ELSEVIER, AMSTERDAM, NL, vol. 56, no. 2, 17 April 2020 (2020-04-17), XP086234670, ISSN: 0924-8579, [retrieved on 20200417], DOI: 10.1016/J.IJANTIMICAG.2020.105984 *
ZHANG JING ET AL: "Pilot trial of high-dose vitamin C in critically ill COVID-19 patients", ANNALS OF INTENSIVE CARE, vol. 11, no. 1, 9 January 2021 (2021-01-09), pages 1 - 12, XP055783083, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s13613-020-00792-3/fulltext.html> DOI: 10.1186/s13613-020-00792-3 *

Similar Documents

Publication Publication Date Title
Cathcart Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy
Patil et al. Theoretical Study and treatment of Novel COVID-19
WO2021209800A1 (fr) Traitement d&#39;une infection humaine par le coronavirus et le virus de la grippe (h1n1) (grippe porcine.)
Tarro Environment and Virus Interactions: Towards a Systematic Therapy of SARS-CoV-2
Krasno et al. Inhalation of penicillin dust
AKSHATA et al. A clinical approach to COVID-19
Kuz et al. The role of the dentist in the treatment of emergency conditions in treating young patients with type 1 diabetes mellitus
Varnni et al. MANAGEMENT OF COVID-19 VIRUS WITH INDIAN SYSTEM OF MEDICINE–A CASE STUDY
Hegazy et al. Our Experience in the Use of Ivermectin in the Fight against COVID‐19
Indra et al. Current scenario for management on COVID-19—A global review
Van Wyk The common cold and influenza: colds & flu
Saul et al. Hospital-based Intravenous Vitamin C Treatment for Coronavirus and Related Illnesses
Jaiswal et al. INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES
Fenton II Sulfanilamide in Otolaryngology: Some Personal Experiences
WO2025104344A1 (fr) Kit comprenant de la vitamine d3, du zinc organique, des acides gras oméga-3 et de la n-acétylcystéine pour le traitement de la grippe et des rhumes et de leurs symptômes, et pour prévenir la propagation d&#39;une infection
RU2102076C1 (ru) Способ лечения острых респираторных заболеваний
Baxtiyarovich et al. BENEFITS AND SIDE EFFECTS OF MEDICATIONS
Bhat A case study of Dengue Fever with Ayurveda line of management
Philpott Influenza: Helping in the fight against flu
Mohan ROLE OF SHALAKYA IN MANAGING COVID-19
Kumar et al. Yoga & naturopathy in COVID Era: An update
Kapustnik et al. The use of herbal medicines with antiviral activity of plant origin for the treatment of diseases caused by COVID-19 infection
RU2170587C1 (ru) Способ лечения острых респираторных вирусных инфекций у детей
McLaren Advancing your practice: Can we make the'common cold'less common?
BİLDEN LEECh aPPLICatIoN

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20737556

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20737556

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 20737556

Country of ref document: EP

Kind code of ref document: A1